Sung Ji Nam
Stock Analyst at Scotiabank
(3.87)
# 638
Out of 5,115 analysts
83
Total ratings
52.17%
Success rate
10.69%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $114.04 | -47.39% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $64.09 | +17.02% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $218.89 | +25.63% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $578.61 | +1.97% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $144.81 | -13.68% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $39.39 | +1.55% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $10.17 | +293.31% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $5.62 | +6.76% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.30 | +207.69% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $2.26 | -11.50% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $102.34 | -28.67% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $18.50 | -35.14% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $370.72 | +21.39% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $41.07 | +50.96% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $38.08 | +15.55% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $20.55 | +70.32% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $2.40 | +150.52% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.22 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $114.04
Upside: -47.39%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $64.09
Upside: +17.02%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $218.89
Upside: +25.63%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $578.61
Upside: +1.97%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $144.81
Upside: -13.68%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $39.39
Upside: +1.55%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $10.17
Upside: +293.31%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $5.62
Upside: +6.76%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.30
Upside: +207.69%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $2.26
Upside: -11.50%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $102.34
Upside: -28.67%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $18.50
Upside: -35.14%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $370.72
Upside: +21.39%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $41.07
Upside: +50.96%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $38.08
Upside: +15.55%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $20.55
Upside: +70.32%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $2.40
Upside: +150.52%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $26.22
Upside: -